4.9 (469) In stock
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.
Gain Therapeutics
Buy Gain Therapeutics Stock - GANX Stock Price Today & News
Gain Therapeutics on X: #Leadership Spotlight: Dr. Terenzio
Gain Therapeutics Promotes Matthias Alder to CEO
Gain Therapeutics (@GainThera) / X
Gain Therapeutics Aktie
Instagram의 Cure GM1 Foundation님 : GAIN Therapeutics published a
Gain Therapeutics - Products, Competitors, Financials, Employees
Gain Therapeutics - Crunchbase Company Profile & Funding
Doubling Down On Gain Therapeutics (NASDAQ:GANX)
Gain Therapeutics: A True Revolution In Drug Development (NASDAQ
Computational Drug Discovery With Gain Therapeutics Matthias Alder
Lorenzo Leoni email address & phone number
